5 Value Stocks In The Healthcare Sector
Portfolio Pulse from Benzinga Insights
The article identifies five value stocks in the healthcare sector, namely Palisade Bio, POINT Biopharma Global, Kiniksa Pharmaceuticals, Ocuphire Pharma, and Pfizer. These stocks are considered undervalued based on their low price-to-earnings (P/E) multiples. The article also provides recent earnings per share data for each company and notes that value stocks may take time to rebound from their undervalued positions.
September 11, 2023 | 2:44 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Kiniksa Pharmaceuticals is identified as a value stock with a P/E of 5.25. Its earnings per share recently reported at $-0.02.
The low P/E ratio indicates that the stock is undervalued, which could attract investors seeking value, potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100
POSITIVE IMPACT
Ocuphire Pharma is identified as a value stock with a P/E of 4.18. Its earnings per share recently reported at $-0.24.
The low P/E ratio indicates that the stock is undervalued, which could attract investors seeking value, potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100
POSITIVE IMPACT
Palisade Bio is identified as a value stock with a P/E of 2.44. Its earnings per share recently reported at $-0.53.
The low P/E ratio indicates that the stock is undervalued, which could attract investors seeking value, potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100
POSITIVE IMPACT
Pfizer is identified as a value stock with a P/E of 9.11. Its earnings per share recently reported at $0.67 and it has a dividend yield of 4.22%.
The low P/E ratio and the high dividend yield indicate that the stock is undervalued, which could attract investors seeking value, potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100
POSITIVE IMPACT
POINT Biopharma Global is identified as a value stock with a P/E of 7.33. Its earnings per share recently reported at $-0.24.
The low P/E ratio indicates that the stock is undervalued, which could attract investors seeking value, potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100